Suchergebnisse - "Kalkeri, Raj"

PubPharm (42)

1

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

enthalten in: bioRxiv.org | 2024

von Bennett, C. | Rivers, E. | Woo, W. | +22

2

XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants

enthalten in: bioRxiv.org | 2024

von Patel, N. | Trost, J. | Guebre-Xabier, M. | +11

3

Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity

enthalten in: Journal of virological methods | 2024

von Hamilton, S. | Zhu, M. | Clark, S. | +8

4

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose : interim analysis of a phase 3, non-inferiority, randomised, clinical trial

enthalten in: The Lancet. Infectious diseases | 2024

von Bennett, C. | Woo, W. | Bloch, M. | +95

5

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

enthalten in: The Journal of infection | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

UpdateOf: medRxiv. 2024 Jan 18;:. - PMID 38293205

6

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants : A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

enthalten in: Microorganisms | 2024

von Cai, Z. | Kalkeri, R. | Zhu, M. | +9

7

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

enthalten in: bioRxiv.org | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

8

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

enthalten in: medRxiv : the preprint server for health sciences | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

UpdateIn: J Infect. 2024 Feb 13;88(3):106119. - PMID 38360356

9

Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults

enthalten in: bioRxiv.org | 2023

von Raiser, F. | Davis, M. | Adelglass, J. | +9

10

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines : a phase 3, randomized, clinical trial

enthalten in: The Journal of infectious diseases | 2023

von Bennett, C. | Rivers, E. | Woo, W. | +22

1
2
3
4
5
Nächster »
[5]